| Dr David Javier Lopez, MD | |
|
300 Np Ave Ste 101, Fargo, ND 58102-4871 | |
| (701) 478-6700 | |
| (701) 478-6705 |
| Full Name | Dr David Javier Lopez |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 29 Years |
| Location | 300 Np Ave Ste 101, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275629719 | NPI | - | NPPES |
| 14661 | Medicaid | ND | |
| 028934 | Other | ND | BC/BS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD60076901 (Washington) | Primary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 10292 (North Dakota) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psychiatry Networks Inc | 0244466449 | 2 |
| St. Joseph's Hospital And Health Center | 0547177560 | 76 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | St. Joseph's Hospital And Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730464108 PECOS PAC ID: 0547177560 Enrollment ID: O20031107000651 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Family Health Care Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710066352 PECOS PAC ID: 1658283650 Enrollment ID: O20031217000272 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Mercy Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801928593 PECOS PAC ID: 7416851381 Enrollment ID: O20031230000336 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Mercy Hospital Of Valley City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477549111 PECOS PAC ID: 8729997564 Enrollment ID: O20040701000086 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Carrington Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558389338 PECOS PAC ID: 0547177552 Enrollment ID: O20040810000314 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Mercy Hospital Of Devils Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790751170 PECOS PAC ID: 9537128681 Enrollment ID: O20041005001141 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Lisbon Area Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811168958 PECOS PAC ID: 4486562873 Enrollment ID: O20041008000975 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Oakes Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477724433 PECOS PAC ID: 3678484722 Enrollment ID: O20041008001150 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Entity Name | Psychiatry Networks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992045108 PECOS PAC ID: 0244466449 Enrollment ID: O20131118001024 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Javier Lopez, MD 300 Np Ave Ste 101, Fargo, ND 58102-4871 Ph: (701) 478-6700 | Dr David Javier Lopez, MD 300 Np Ave Ste 101, Fargo, ND 58102-4871 Ph: (701) 478-6700 |
News Archive
The American Society of Hematology is pleased to announce the five recipients of the 2010 ASH Research Training Award for Fellows, a grant that encourages junior researchers to pursue careers in academic hematology by supporting protected time to conduct research during their fellowship training.
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
As a person ages, perception declines, accompanied by augmented brain activity. Learning and training may ameliorate age-related degradation of perception, but age-related brain changes cannot be undone. Rather, brain activity is enhanced even further, but for other reasons and with different outcomes.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 6 days ago
Susan L Scarberry, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 1st Ave S, Fargo, ND 58103 Phone: 701-234-4036 Fax: 701-234-4160 | |
Charlotte Marie Andersen, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 510 4th Street S, Fargo, ND 58107 Phone: 701-476-7200 | |
Dr. Lawana Marie Burtnett, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 510 4th St S, Fargo, ND 58103 Phone: 701-476-7200 | |
Dr. Ravinda Samaraweera, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 1st Ave S, Fargo, ND 58103 Phone: 701-234-4036 Fax: 701-234-4160 | |
Dr. Timothy T Vo, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2624 9th Ave S, Southeast Human Service Center, Fargo, ND 58103 Phone: 701-298-4500 Fax: 701-298-4400 | |
Karis Antonia Stenback Irving, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2101 Elm St Ne, Fargo, ND 58102 Phone: 615-918-0639 Fax: 612-749-3990 | |
Amna Masood, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 736 Broadway N, Fargo, ND 58102 Phone: 701-234-2000 Fax: 701-234-2345 |